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Abstract 
 
Objective:  Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss 
in older adults and may lead to substantial functional impairment.   We investigated the relative 
contributions of ophthalmological, psychological, medical, and cognitive factors as predictors of 
vision function to broaden our knowledge of its varied determinants. 
 
Methods:  Baseline evaluation of 241 older outpatients with advanced AMD who were enrolled 
in a clinical trial testing the efficacy of a behavioral intervention to improve vision function.  
Vision function was characterized as an interval-scaled, latent variable of visual ability based on 
the near vision subscale of the National Eye Institute Vision Function Questionnaire-25 plus 
Supplement. 
 
Results:  Visual ability was highly correlated with visual acuity.  However, a multivariate model 
revealed that patients’ coping strategies and cognitive function contributed to their ability to 
perform near vision activities independent of visual acuity.  
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Conclusions:  Patients with AMD vary in their coping strategies and cognitive function as well as 
their visual acuity, and that variability in these factors determines patients’ self-report of vision 
function.   Understanding patients’ coping mechanisms and cognition may help to increase the 
precision of vision rating scales and suggest new interventions to improve vision function and 
quality of life of patients with AMD.   
 
ClinicalTrials.gov Identifier: NCT00572039  
 
 
Introduction 
 
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older 
adults, with almost 2 million having advanced disease (i.e., neovascular AMD or geographic 
atrophy) and over 7 million having early signs.1  Their number will double by 2020, dramatically 
increasing the number of visually impaired adults who cannot read, drive, or live independently.2  
Fortunately, the anti-vascular endothelial growth factor (VEGF) antibodies ranibizumab and 
bevacizumab have greatly improved neovascular AMD’s prognosis.3  The MARINA and 
ANCHOR trials found that ranibizumab prevented vision loss in 95.5% of subjects.3-5 About 30% 
gained 15 or more letters and 50% had improved mental health.6 Although these are 
unprecedented outcomes, the converse is informative: the vision function of 70%, and the 
mental health of 50%, did not improve to this extent.  Patients with visual acuity worse than 
20/70 in the better eye after treatment, for example, would still have disabling impairment and 
rehabilitative needs.  Thus, despite the success of anti-VEGF treatment, AMD-related disability 
remains a major public health problem.7  
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To measure AMD-related disability many investigators have used the National Eye Institute 
Visual Function Questionnaire (NEI VFQ).8,9 Massof and Fletcher (2001) demonstrated that the 
NEI-VFQ items that assess difficulty with everyday tasks yield a latent visual ability variable that 
strongly relates to visual acuity.10  The correlation of 0.523, however, indicates that visual acuity 
accounts for only about 27% of the variance, and suggests that other factors influence NEI VFQ 
scores.  Depression and general health are two such factors.11,12 Other clinical variables may 
also contribute and, unless accounted for, may introduce unmeasured sources of variability or 
“noise” into disability measurements in patients with AMD.   
 
In this study, we investigated the influence of coping strategies, depression, physical health, and 
cognition on NEI VFQ scores that we obtained at baseline in a sample of older patients with 
AMD who were enrolled in the “Improving Function in AMD Trial” (IF-AMD).   IF-AMD is a 
randomized, controlled clinical trial that compares the efficacy of Problem-Solving Therapy with 
Supportive Therapy to improve vision function in patients with AMD.  
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Methods 
 
This study reports baseline data obtained prior to randomization into the IF-AMD clinical trial.   
We recruited 241 patients with AMD from the retina clinics associated with the Wills Eye 
Institute (WEI) in Philadelphia, PA from 2006 to 2010, and randomized subjects to Problem-
Solving Therapy (PST) or Supportive Therapy in a 1:1 allocation ratio.13,14 The primary aims of 
the IF-AMD trial are to test the immediate (3-months) and longer term (6-months) efficacy of 
PST to improve the primary outcome of vision function.   
 
The inclusion criteria were: 1) age 65 years or older; 2) bilateral AMD (neovascular and/or dry); 
3) visual acuity between 20/70 and 20/400 [inclusive; (best corrected)] in the better-seeing eye, 
and no worse than 20/400 in the fellow eye, and 4) moderate difficulty in at least one valued 
vision function goal.  The exclusion criteria were: 1) presence of uncontrolled glaucoma, diabetic 
retinopathy, or planned cataract surgery within 6 months; 2) dementia, using a version of the 
Mini-Mental Status Examination (MMblind) that omits vision-dependent items;15 3) presence of 
life-threatening illness; and 4) residence in a skilled nursing facility.  All subjects signed an 
informed consent form approved by Thomas Jefferson University’s Institutional Review Board. 
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At baseline, a research nurse conducted clinical assessments in subjects’ homes and gathered 
demographic information and assessed the following clinical variables: 
 
Vision:  Best-corrected vision was assessed with the Lighthouse Ferris-Bailey ETDRS Chart to 
measure distance visual acuity and the Pelli-Robson Contrast Sensitivity chart to measure 
contrast sensitivity.  Near and distance acuities were assessed at 16 inches and 5 feet, 
respectively.  A gooseneck lamp was used to standardize luminance levels.  For statistical 
analyses, log transformations were used (i.e., logMAR and log contrast) for visual acuity and 
contrast sensitivity, respectively.  
 
Physical Health:  We used the Chronic Disease Score, which provides an index of medical 
comorbidity based on a weighted sum of medications taken for chronic illness, and the 
Multilevel Assessment Inventory Health Conditions Check List, which lists specific acute and 
chronic conditions.16,17 
 
Depression:  We used the Patient Health Questionnaire-9 (PHQ-9) to assess depression.  The 
PHQ-9 includes the 9 criteria that comprise DSM-IV diagnoses of major or minor depressive 
disorders.18   It is a dual-function instrument in that it generates both categorical diagnoses of 
depression and grades depressive symptom severity as a continuous measure.  Symptoms are 
scored on an ordinal scale from 0 (not at all) to 3 (every day).  The raw score for each patient is 
the sum of symptom scores across the 9 items.  The raw scores range from 0 to 27 with higher 
scores indicating worse depression.  Symptoms are scored from 0 (not at all) to 3 (every day).  
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Cognition:  We administered the Animal Fluency Test (AFT) to obtain a brief assessment of 
cognitive function that is relevant to the completion of daily activities.19 This verbal fluency test 
requires subjects to name as many different animals as possible in 60 seconds and is scored as 
the number of animals named.  The test requires semantic knowledge of categories, vocabulary 
storage, speeded mental processing, and intact executive function.  A reduction in the number 
of retrieved items, repetition of the same word, and listing of disqualified words indicate difficulty 
with sustained output, concentration, and retrieval.  The average (standard deviation) score for 
white females aged 70 -89 with 12 years of education is 17.2 (4.2).   
 
Vision Function:  We used the NEI VFQ-25 plus Supplement, which consists of 25 items and a 
supplement of 14 additional items, derived from the original 52-item NEI VFQ.8,9  It is used to 
assess self-reported vision function and generates 11 subscale scores and an overall score.  In 
this investigation, we focused on items that are included in part 2 of the NEI-VFQ because they 
all require difficulty ratings of vision-dependent activities that many patients highly value.  In 
particular, the near vision subscale consists of 6 items rating difficulties with: reading newsprint; 
doing housework or hobbies (e.g., sewing, using tools); finding something on a crowded shelf; 
reading small print on a medication bottle or legal form; determining if bills are accurate; and 
performing personal hygiene tasks (e.g., shaving, putting on makeup).  Subjects rate these 
items on a 1 to 5 ordinal scale, with higher numbers indicating increasing levels of difficulty (i.e., 
no difficulty, a little difficulty, moderate difficulty, extreme difficulty, or stopped doing this 
because of your eyesight), or they can respond that they stopped doing the activity described by 
the item for other reasons/not interested(scored as missing data).  Previous studies have 
demonstrated that the items of the near vision subscale are responsive to low vision 
rehabilitation and anti-VEGF treatment and can be used to estimate an interval scale suitable 
for the analyses we conducted.6, 10, 20-23 
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Coping Strategies:  We used the Optimization in Primary and Secondary Control Scale (OPS) to 
assess the characteristic approaches, or control strategies, that subjects enact to achieve 
valued goals.24  This instrument draws from the life span theory of control which posits that 
people use different health-related control strategies to greater and lesser extents when faced 
with adverse health conditions.  We selected the OPS because of its applicability to patients 
with chronic disabling diseases like AMD who must find ways to adjust to vision loss.   The 
OPS’s reliability and validity and psychometric properties have been demonstrated in studies of 
older persons and patients with AMD.25  Brennan et al (2004) adapted items specifically for 
patients with vision loss.26 The OPS scale is divided into 4 control strategies, each comprised of 
8 items rated from 0, “never true” to 4, “almost always true”, yielding a raw score range of 0 to 
32 for each control strategy; higher scores indicate greater use of the particular strategy.   
 
Selective primary control refers to the investment of behavioral resources (i.e., time, effort, 
skills) into pursuing a goal.  Representative items are, “I do whatever I can to continue my 
everyday activities despite my vision problem” and “If I invest enough time, I can continue my 
everyday activities despite my vision problem.”  Selective secondary control serves to enhance 
and maintain motivation and commitment to a goal, particularly when obstacles (i.e., vision loss) 
make achieving the goal difficult.  Items include, “I think how important it is to me to keep up my 
daily activities in spite of my vision problem” and “I tell myself that it’s up to me to make sure my 
vision problem does not interfere with what I want to do”.  Compensatory primary control refers 
to the recruitment of help from others or the use of assistive devices (e.g., magnifiers) when an 
individual has difficulty attaining a goal.  Items include, “If there is something that I can no longer 
do because of my vision problem, I actively seek out help from others” and “If I’m having trouble 
doing something because of my vision problem, I look for a device or aid that will help get it 
done.”  Compensatory secondary control refers to goal disengagement when the goal becomes 
unattainable, thereby freeing up the person to pursue other goals that are attainable.  It also 
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includes self-protective strategies such as focusing on successes in other domains.  Typical 
items include, “I can accept that there are things I can no longer do since I started having 
problems with my vision” and “I spend my time doing what I can do, rather than struggling with 
the things that have become difficult because of my vision problem.”   
 
Statistical Methods: 
 
Descriptive statistics for baseline demographic and clinical variables are presented as means 
and standard deviations (SD) for continuous data and frequencies and percents for categorical 
data.  We used a latent variable model to investigate the relationship between the 6 items of the 
NEI-VFQ near activities subscale and various clinical and psychological characteristics.27, 28 
Because we expect subject responses to depend on multiple variables, we employed a 
structural equation model that assumes each subject has an ability to perform near activities 
(i.e., the composite latent variable) manifested by the 6 NEI VFQ items.  The ability to perform a 
specific near vision NEI VFQ activity item is obtained by multiplying the factor loading for that 
item by the underlying latent ability.  A subject should perform at a given level for a specific item 
when the product of the item factor loading and the underlying ability crosses a given threshold 
for that item.  We assumed that the ability to perform near activities is a linear function of one or 
more clinical and/or psychological characteristics (e.g., age, visual acuity, cognition, coping 
strategies).  That is, we modeled the ability to perform near activities using a linear regression 
model that assumes the component variables have independent effects on the estimated 
functional ability variable.   We considered each of the potential predictors individually and 
selected all with p<0.20 for inclusion in a multivariable model.  We used the latter liberal 
statistical criterion to maximize our ability to detect any significant associations.   Latent variable 
models were fit using Mplus Version 6.29 
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Results 
 
Subject clinical and psychological characteristics are summarized in Table 1.  The mean 
[standard deviation (SD)] age of subjects was 82.8 (6.9) years and 63.1% were women.  One 
hundred two (42.3%) had received anti-VEGF injections.  Depressive symptoms, as reflected by 
mean PHQ-9 scores, were low in the sample as a whole; however, 31 subjects (12.9%) met 
criteria for a depressive disorder.  This rate is consistent with a recent study of depression 
prevalence rates in patients with AMD.30  
 
The value of the latent visual ability variable was estimated for each subject from the 
multivariable model.  Estimated values ranged from -4.3 to 2.85 with a mean of 0 and a 
standard deviation of 1.2.  Figure 1 depicts the relationship of the latent visual ability with visual 
acuity and shows the strong relationship between the two variables but also the considerable 
variability that remains.  Table 2 shows the results of the univariable models wherein we 
evaluated the relationship between the predictor variables and the latent visual ability variable.  
The values represent the increase in visual ability associated with a one unit increase in that 
predictor.  For example, a one-unit increase in contrast sensitivity was associated with a 0.32 
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increase in visual ability.  Of the 12 possible predictors, visual acuity, contrast sensitivity, 
selective primary control, compensatory primary control, selective secondary control, the 
cognitive verbal fluency score (Animal Fluency Test), and age were statistically significantly 
associated with the latent visual ability variable (at the p<0.20 level) and were included in the 
multivariate model.   Table 3 shows the results of the multivariable model wherein we 
considered the unique effect of each of the significant variables of the univariable model after 
controlling for the effects of the other variables.  This model reveals that visual acuity, 
compensatory primary control, selective secondary control, and verbal fluency were 
independently associated with self-reported difficulty with near activities.   
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Discussion 
 
We found that patients with AMD vary in their coping strategies and cognitive function as well as 
their visual acuity, and that variability in these factors determines patients’ self-report of vision 
function independent of the effect of visual acuity.  The subjects we studied were drawn from 
outpatients of an academic retinavitreous practice, had specific vision characteristics, and had 
enrolled in a clinical trial to improve vision function.  These unique characteristics limit the 
generalizability of our findings.  Nevertheless, the sample represents a large group of patients 
commonly seen in ophthalmologic practices whose severity of vision loss and disability present 
a challenge both to the patients and their ophthalmologists.    
 
The strengths of the study include the large sample size, systematic ascertainment and 
assessment of subjects whose visual, affective, medical, and functional characteristics were 
evaluated with instruments of known reliability and validity, and the use of latent variable 
modeling to estimate an interval scale of visual ability based on the NEI VFQ near vision 
subscale.  Although previous studies have demonstrated the NEI VFQ’s validity in a 
conventional sense, they have used ordinal rather than interval-scaled item responses (i.e., 
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categorical responses where the difference between responses may not be the same, versus 
numerical values where the difference between values is the same).  Because ordinal 
responses have uncertain quantitative relationships with each another, there is an increased 
risk of measurement error.31-33 Our use of an interval-scaled, latent visual variable yields a more 
precise measure that has enabled us to identify new clinical variables that illuminate patients’ 
perceptions of disability.  This study’s limitations, however, include lack of measures of central 
scotomas, glare sensitivity, binocular vision, reading, and other performance-based tests that 
might better discriminate patients in terms of the direct effects of AMD on ability. 
All vision-dependent tasks require a specific level of vision to perform them successfully and 
independently.  A patient’s rating of “difficulty” reflects the difference between the level of 
required vision and the patient’s visual ability which depends, our data show, on his or her visual 
acuity as well as coping strategies and cognitive function.34  We found that higher use of the 
coping strategy of compensatory primary control, such as relying on others for help and using 
optical devices, was associated with greater difficulty with near vision activities.  This intuitively 
correct association indicates that this coping strategy, which aims to increase a patient’s control 
over his or her life circumstances, represents a healthy psychological adaptation to vision loss 
and contributes to what drives their perceptions of disability.  This finding provides support for 
ophthalmologists’ recommendations to patients with AMD to pursue low vision rehabilitative 
interventions.  
 
A second control strategy that was associated with visual ability was selective secondary 
control.  A higher use of this strategy, which represents the willingness to persevere in the face 
of potential failure, predicted lower ratings of vision disability.  Patients with AMD who utilize this 
strategy tend to look forward to the positive consequences of achieving a goal even as they 
work hard to achieve it.  Understandably, they would tend to perceive less difficulty than others 
who lack the same level of motivation but who are otherwise similar in their vision 
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characteristics. The treatment implication of this finding is that interventions that strengthen the 
ability to tolerate frustration and keep on trying, like cognitive behavioral therapies, might reduce 
disability levels in vulnerable people.  Interestingly, although depression is often related to vision 
function in patients with vision loss, in this sample it was not.35-37 The unique characteristics of 
the sample (i.e., patients who enrolled in a clinical trial who had, on average, low levels of 
depressive symptoms), constrained the scores and limited the ability to detect any significant 
associations. 
 
Better scores on a cognitive task that assesses verbal fluency were associated with lower 
perceived vision function difficulties.  Greater ability in this cognitive domain indicates better 
sustained output, concentration, and executive function.38 The latter refers to a group of 
complex cognitive abilities that include organizing, understanding, and appreciating information, 
and planning, initiating, and monitoring behavior which, in turn, enables rational problem-
solving.39 Thus, we might expect that patients with AMD who possess these cognitive skills 
would find ways to compensate for their vision disabilities and devise strategies to reduce task 
difficulty.  This interpretation agrees with other studies which find that coexisting visual and 
cognitive impairments are highly disabling, and that patients with AMD who relinquish valued 
activities are at risk for incident dementia.40-43 These studies emphasize the importance of 
assessing cognition in AMD studies, even in subjects without dementia, and encouraging 
patients to remain active despite vision loss to promote optimal cognitive and physical health.   
 
The introduction of anti-VEGF treatments for AMD has spared many patients from progressive 
vision loss and severe disability.  Although these treatments have expanded rapidly in the 
community in recent years, we know little of their impact outside of clinical trials.44 Our data 
suggest that recognizing the role of patients’ coping strategies and cognition may inform 
outcome studies of anti-VEGF treatment and may have direct implications for the clinical care of 
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patients.  For researchers who use the NEI VFQ in clinical trials, characterizing subjects’ coping 
strategies and cognitive function may improve the precision of vision rating scales, reduce 
measurement error, and suggest new interventions to improve vision function and quality of life.  
For ophthalmologists in clinical practice, encountering patients whose vision function is worse 
than expected given their visual acuity should prompt brief assessments of how patients are 
coping or of their cognition.   These assessments might then lead to referrals for neurological or 
psychiatric evaluation to identify modifiable factors that may optimize functional vision.  For 
highly motivated patients who use active control strategies, positive reinforcement and referral 
to low vision rehabilitation may help them achieve their goals.  For patients who more passively 
accept their disability, sympathetic understanding of their functional limitations and expressions 
of support may be valuable interpersonal interventions.  From the clinical standpoint, these 
findings highlight the need for evidence-based models to improve care at the interface of 
ophthalmology and psychiatry and to develop a comprehensive national health care policy to 
assist older persons with their visual needs. 
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Figure 1.  Scatterplot of Visual Ability vs. Visual Acuity 
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Table 1.  Clinical and Vision Sample Characteristics of the Sample (N = 241) 
 
Demographic and Medical Characteristics 
   Age1 82.8 (6.9) 
   Female2 153 (63.1) 
   Education, yrs1 13.2 (3.1) 
  Chronic Disease Score1,3 5.6 (2.9) 
Vision Characteristics 
   Best eye logMAR1, 4 .57 (.29) 
   Best eye log contrast1, 5 .69 (.41) 
   Anti-VEGF treatment in past 3 months2 102 (42.3) 
   NEI-VFQ near activities1,6 53.3 (20.7) 
Coping Strategies 
   Selective Primary Control (range:  6 to 24)1,7 22.3 (2.4) 
   Compensatory Primary Control (range:  9 to 36)1,7 26.7 (6.0) 
   Selective Secondary Control (range:  9 to 36)1,7 30.1 (4.9) 
   Compensatory Secondary Control (range:  7 to 28)1,7 21.8 (4.0) 
Depression 
  PHQ-9 Scores1,8 (range 0 to 27) 1.3 (2.5) 
Cognition 
  Animal Fluency Test1,9 14.8 (4.7) 
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1
 mean, SD 
2
 n, % 
3 High score is worse medical morbidity 
4
 High score is worse vision. 
5
 High score is better contrast. 
6
 Scored from 0 to 100 with higher scores indicating better function. 
7
 A higher score is more frequent use of the control strategy. 
8
 A higher score is worse depression. 
9
 A higher score is better cognitive function. 
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Table 2.  Bivariate Relationships of Predictor Variables to Vision Function  
 
Variable Estimatea 
95% Confidence 
Interval p-value 
Visual Acuity -2.02 -2.63 -1.41 <.001 
Compensatory Primary Control -0.046 -0.071 -0.020 <.001 
Animal Fluency Test 0.056 0.024 0.088 0.001 
Age -0.030 -0.052 -0.008 0.006 
Selective Primary Control 0.08 0.018 0.14 0.010 
PHQ Severity -0.055 -0.12 0.005 0.073 
Selective Secondary Control 0.027 -0.004 0.057 0.080 
Contrast Sensitivity 0.32 -0.05 0.68 0.090 
Chronic Disease Score -0.025 -0.075 0.025 0.330 
Education 0.020 -0.028 0.068 0.410 
Gender (male vs. female) 0.068 -0.24 1.31 0.660 
Compensatory Secondary Control 0.005 -0.032 0.041 0.810 
 
a
 Estimates are increase in visual ability associated with one unit-increase in each predictor 
variable.   
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Table 3.  Multivariable Relationships of Predictor Variables to Vision Function: 
Regression Parameters 
 
Variable Estimate 95% CI p-value 
Visual Acuity -1.93 -2.59 -1.27 <0.001 
Compensatory Primary Control -0.076 -0.11 -0.044 <0.001 
Animal Fluency Test 0.054 0.019 0.090 0.003 
Selective Primary Control 0.08 0.01 0.018 0.14 
Selective Secondary Control 0.047 0.003 0.090 0.036 
Contrast Sensitivity 0.20 -0.21 0.61 0.330 
PHQ Severity -0.032 -0.10 0.035 0.350 
Age -0.008 -0.033 0.016 0.510 
 
 
 
 
 
 
